Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Summary

This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Parkinson Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

45 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Vikas Kotagal

Last updated on ClinicalTrials.gov

March 31, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites